News | September 25, 2013

Studies Show Excellent Outcomes With Strut-based Breast Brachytherapy

Early-stage breast cancer treatment demonstrates high rates of survival and local control

September 25, 2013– Cianna Medical Inc., announced results of two new studies showing excellent longer-term outcomes with the SAVI (strut adjusted volume implant) breast brachytherapy applicator, including low recurrence rates, few toxicities, excellent cosmetic outcomes and high rates of survival. A third study demonstrated SAVI’s ability to precisely deliver radiation while avoiding critical structures. SAVI is a strut-based applicator that delivers accelerated partial breast irradiation (APBI), a five-day course of targeted radiation for early-stage breast cancer.

Data came from the SAVI Collaborative Research Group (SCRG), which studies the long-term outcomes of women treated with ABPI with SAVI and will be presented as posters at the 55th annual meeting of the American Society for Radiation Oncology (ASTRO), Sept. 22-25, 2013, in Atlanta.

“APBI is an accepted treatment for certain women with early-stage breast cancer, with multiple Phase II and III clinical trials demonstrating its efficacy and safety,” said Robert Kuske, M.D., co-principal investigator of the SCRG and a radiation oncologist at Arizona Breast Cancer Specialists, Phoenix, Ariz. “This new data further validates strut-based brachytherapy as a safe and effective method for delivering partial breast radiation, which means more women will have access to a treatment that delivers highly targeted radiation with much greater convenience.”

The first study detailed outcomes with the most mature follow-up of patients treated with strut-based APBI. The multi-institutional study examined 101 patients with a median follow-up of 4.5 years, reporting very low toxicity rates (< 3%) and excellent local control (2%). Overall and cause-specific actuarial survival rates were 100 percent.

“On longer follow-up, strut-based brachytherapy continually meets the standards we look for in a safe and effective breast cancer treatment – very high rates of survival and local control, few toxicities and excellent cosmetic outcomes,” said lead author Catheryn Yashar, M.D., a radiation oncologist at UC San Diego’s Moores Cancer Center, La Jolla, Calif., and co-principal investigator of the SCRG.

A second study of a larger population (576 patients) with a median follow-up of three years reported similarly favorable results, including low toxicities and a local recurrence rate of less than 2.5 percent. Overall and cause-specific actuarial survival rates were 99.5 percent.

“Strut-based brachytherapy makes it possible to approach breast cancer treatment in a more sophisticated way. SAVI’s unique design enables physicians to customize radiation specific to the patient, allowing us to offer a very personalized level of care,” said lead author Robert Hong, M.D., a radiation oncologist at Virginia Hospital Center, Arlington, Va.

The final study analyzed the radiation treatment plans for over 1,000 patients in the SCRG. The data demonstrated SAVI’s flexibility in shaping the radiation dose cloud, which researchers concluded protects critical structures and makes brachytherapy an option for patients who would not be candidates for other single-entry devices. The poster was presented by medical physicist Jay Reiff, Ph.D, a professor in the Department of Radiation Oncology at Drexel University Hospital, Philadelphia, Pa.

For more information: www.ciannamedical.com

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at